Wikisage, the free encyclopedia of the second generation, is digital heritage

Daniel Peterson: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(→‎Affiliations: ref fix)
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
'''Daniel Peterson''' is an [[United States|American]] [[physician]] in private practice in the state of [[Nevada]], and has been described as a "pioneer" in the treatment of [[chronic fatigue syndrome]] (CFS).<ref name="Patient Zero">Verrillo EF, Gellman LM (1998), "Chronic Fatigue Syndrome: A reatment Guide", Macmillan, 152p, ISBN=0312180667, [http://books.google.com/books?id=VtHlTVfToiQC&pg=PA152&lpg=PA152&dq=peterson+first+used+ampligen+in+cfs&source=web&ots=G9yDE0a_8y&sig=rjllhpnZ_YSyGCcWI1W5pJk3GJ8&hl=en&sa=X&oi=book_result&resnum=2&ct=result 20090606]</ref><ref name="HHV6BOD">(2004), "HHV-6 Foundation Board of Directors", HHV-6 Foundation, [http://www.hhv-6foundation.org/bod.htm 20090318]</ref> He graduated from the University of Rochester School of Medicine, [[Rochester]], New York, in 1976 and was an intern and resident at the [[University of Utah Medical Center]] from 1976-1979. In 1979 he became a diplomat of the [[American Board of Internal Medicine]].<ref name="WPInst">(2008), "Executive staff", The Whittemore Peterson Institute, [http://www.wpinstitute.org/about/about_execboard.html 20090111]</ref> He is president of Sierra Internal Medicine of [[Incline Village]], established in 1981.<ref name="Sierra">
'''Daniel Peterson''' is an [[United States|American]] [[physician]] in private practice in the state of [[Nevada]], and has been described as a "pioneer" in the treatment of [[central nervous system]] [[infection]]s<ref name="HHV6BOD">(2004), "HHV-6 Foundation Board of Directors", HHV-6 Foundation, [http://www.hhv-6foundation.org/bod.htm 20090318]</ref> and [[chronic fatigue syndrome]] (CFS).<ref name="Patient Zero">Verrillo EF, Gellman LM (1998), "Chronic Fatigue Syndrome: A reatment Guide", Macmillan, 152p, ISBN=0312180667, [http://books.google.com/books?id=VtHlTVfToiQC&pg=PA152&lpg=PA152&dq=peterson+first+used+ampligen+in+cfs&source=web&ots=G9yDE0a_8y&sig=rjllhpnZ_YSyGCcWI1W5pJk3GJ8&hl=en&sa=X&oi=book_result&resnum=2&ct=result 20090606]</ref> He graduated from the University of Rochester School of Medicine, [[Rochester]], New York, in 1976 and was an intern and resident at the [[University of Utah Medical Center]] from 1976-1979. In 1979 he became a diplomat of the [[American Board of Internal Medicine]].<ref name="WPInst">(2008), "Executive staff", The Whittemore Peterson Institute, [http://www.wpinstitute.org/about/about_execboard.html 20090111]</ref> He is president of Sierra Internal Medicine of [[Incline Village]], established in 1981.<ref name="Sierra">
(2008), "Sierra Internal Medicine", Dun and Bradstreet, [http://www.manta.com/coms2/dnbcompany_f4xfgj 20090112]</ref>
(2008), "Sierra Internal Medicine", Dun and Bradstreet, [http://www.manta.com/coms2/dnbcompany_f4xfgj 20090112]</ref>


==Work in chronic fatigue syndrome==
==Work on myalgic encephalomyelitis / chronic fatigue syndrome ==
Peterson with Paul Cheney, was a treating physician at Incline Village during an outbreak of chronic fatigue syndrome that began in 1984 in the [[Lake Tahoe]] region.<ref name="PTL">{{cite video | people = Sam Donaldson, Nancy Snyderman, Paul Cheney, David Bell, Elaine DeFreitas, Hillary Johnson, PWC's, Paul Pollard, Mrs. Dailor, Philip Lee | title = Sick & Tired | medium = Television | publisher = ABC News | location = | year2 =1996-03-27}}</ref> From 1984-87, the illness was recorded in 259 patients in the area by the two physicians. The Lake Tahoe outbreak became the subject of several studies by Peterson and others. In 1995 Peterson and other investigators started conducting a 10 year follow up study on patients seen during the outbreak. The study results were published in 2001 by the ''Journal of Chronic Fatigue Syndrome''.<ref name="Strickland">{{cite journal | author = Paula S. Strickland, PhD, MPH; Paul H. Levine, MD; Daniel L. Peterson, MD; Karen O'Brien, BS; Thomas Fears, PhD | title = Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an Outbreak | journal = Journal of Chronic Fatigue Syndrome | volume = 9 3/4 | issue = | pages = 3–14 | year = 2001 | url = http://dceg.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?page=abstract&ID=6563&project=dceg |format= | doi = }}</ref> In the 2000 CFS documentary [[I Remember Me]], Peterson was interviewed about his some of his experiences during the Lake Tahoe outbreak.<ref name="Ebert">{{cite web | last =Ebert | first =Roger | authorlink = rogerebert.com | coauthors = | title = I remember Me | work = Movie Review | publisher = Roger Ebert Chicago Suntimes | date =December 7, 2001 | url = http://rogerebert.suntimes.com/apps/pbcs.dll/article?AID=/20011207/REVIEWS/112070301/1023 | format = HTML | doi = | accessdate = 2009-01-07}}</ref>  
Peterson with [[Paul Cheney]], was a treating physician at [[Incline Village]] during an outbreak of chronic fatigue syndrome that began in 1984 in the [[Lake Tahoe]] region.<ref>Donaldson S, Snyderman N, Cheney P, Bell D, DeFreitas E, Johnson H, PWC's, Pollard P, Mrs. Dailor, Lee P (1996), "Sick & Tired - Chronic Fatiguue Syndrome", Primetime Live (tv), ABC News, Mar 27, [http://abcnewsstore.go.com/webapp/wcs/stores/servlet/DSIProductDisplay?catalogId=11002&storeId=20051&productId=2013126&langId=-1&categoryId=100024 20090609]</ref> From 1984-87, the illness was recorded in 259 patients in the area by the two physicians. The Lake Tahoe outbreak became the subject of several studies by Peterson and others. In 1995 Peterson and other investigators started conducting a 10-year follow-up study on patients seen during the outbreak. The study results were published in 2001 by the [[Journal of Chronic Fatigue Syndrome]].<ref>Strickland PS, Levine PH, Peterson DL, O'Brien K, Fears T (2001), "Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an Outbreak", Journal of Chronic Fatigue Syndrome 9(3/4):3–14 [http://dceg.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?page=abstract&ID=6563&project=dceg 20090609]</ref> In the 2000 CFS documentary [[I Remember Me]], Peterson was interviewed about some of his experiences during the Lake Tahoe outbreak.<ref>Snyder KA (2000), ''I Remember Me'', Loka Motion Productions, Inc., [http://irememberme.com/ 20090609]</ref>  


In 1988, Peterson was the first physician to treat an extremely ill person diagnosed with CFS with the experimental drug [[Ampligen]] by obtaining compassionate use permission from the [[U.S. Food and Drug Administration]]. [[Quantitative]] improvement in the first patient enabled the next pilot study of Ampligen in CFS patients by Peterson and other researchers. During the 1990 CFIDS Conference in Charlotte, North Carolina, Peterson described positive results in 15 CFS patents after he treated them with Ampligen for approximately 6 months.<ref name="Patient Zero">{{cite book | last = | first = | authorlink = | coauthors = Erica F. Verrillo, Lauren M. Gellman | title = Chronic Fatigue Syndrome: A reatment Guide | publisher = Macmillan | year = 1998 | location = | page = 152 | url = http://books.google.com/books?id=VtHlTVfToiQC&pg=PA152&lpg=PA152&dq=peterson+first+used+ampligen+in+cfs&source=web&ots=G9yDE0a_8y&sig=rjllhpnZ_YSyGCcWI1W5pJk3GJ8&hl=en&sa=X&oi=book_result&resnum=2&ct=result | doi = | isbn = 0312180667, 9780312180669 }}</ref> In 1990 and 1991 Peterson was one of four principal investigators for the FDA approved phase II randomized [[placebo]] controlled [[double blind]] study of the experimental [[intravenous]] drug Ampligen. The drug was administered in his Incline Village facility and three other sites.<ref name="Amp II">{{cite book |author=Johnson, Hillary |title=Osler's web: inside the labyrinth of the chronic fatigue syndrome epidemic |publisher=Crown Publishers |location=New York |year=1996 |page= 385 |isbn=0-517-70353-X |oclc= |doi= |accessdate=}}</ref> Peterson and others reported there was statistically significant improvement in the patients receiving Ampligen.<ref name="Amp II results">{{cite journal |author=Strayer DR, Carter WA, Brodsky I, ''et al'' |title=A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome |journal=Clin. Infect. Dis. |volume=18 Suppl 1 |issue= |pages=S88–95 |year=1994 |month=January |pmid=8148460 |doi= |url=}}</ref> He is a principal investigator of the FDA-approved open label safety and efficacy phase III drug study of Ampligen for treatment of chronic fatigue syndrome.<ref name="Amp 511">{{cite web | last = | first = | authorlink = | coauthors = | title = Study of Ampligen in Chronic Fatigue Syndrome | work = | publisher = U.S. National Institutes of Health | month = September | year = 2005 | url = http://clinicaltrials.gov/ct2/show/NCT00215813 | format = HTML | doi = | accessdate = 2009-01-06}}</ref> According to the drug developer Hemispherx Biopharma, a [[New Drug Application]] for Ampligen treatment of chronic fatigue syndrome has been filed with the FDA but has not yet been approved.<ref name="hemospherx">"[http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A& Business Description: HEM Research, Inc.]" 1986. Retrieved on [[February 25]], [[2007]].</ref><ref name="Hemispherx1">{{cite web | last = | first = | title = Ampligen | publisher = Hemispherx Biopharma | date = | url = http://www.hemispherx.net/content/rnd/drug_candidates.htm | format = htm | accessdate =2008-04-26}}</ref>
In [[1988]], Peterson was the first physician to treat an extremely ill person diagnosed with CFS with the experimental drug [[Ampligen]] by obtaining compassionate use permission from the [[U.S. Food and Drug Administration]]. [[Quantitative]] improvement in the first patient enabled the next pilot study of Ampligen in CFS patients by Peterson and other researchers. During the 1990 [[Cambridge]] Easter Symposium on [[myalgic encephalomyelitis]] and chronic fatigue syndrome in the [[United Kingdom]], Peterson described positive results in 15 patients who satisfied the 1988 Holmes criteria for CFS and also showed evidence of [[encephalopathy]], after he treated them with Ampligen for approximately 6 months.<ref>Peterson DL, Strayer DR, Bastien SB, Henry B, Ablashi DV, Breaux EJ, Walters DJ, Gillespie DR, Carter WA, "Clinical Improvements Obtained with Ampligen in Patients with Severe Chronic Fatigue Syndrome and Associated Encephalopathy", in: Hyde BM (ed.) (1992), "The Clinical and Scientific Basis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome", Nightingale Research Foundation, Ottawa, Canada with editorial and conceptual advice from Levine P and Goldstein J., 724+23p, ISBN 0-9695662-0-4, ch.71, p.634-638</ref><ref name="Patient Zero"/> In 1990 and 1991 Peterson was one of four principal investigators for the FDA approved phase II randomized [[placebo]] controlled [[double blind]] study of the experimental [[intravenous]] drug Ampligen. The drug was administered in his Incline Village facility and three other sites.<ref>Johnson H (1996), "Osler's web: inside the labyrinth of the chronic fatigue syndrome epidemic", New York: Crown Publishers, p385, ISBN 0-517-70353-X</ref> Peterson and others reported there was statistically significant improvement in the patients receiving Ampligen.<ref>Strayer DR, Carter WA, Brodsky I, ''et al.'' (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin.Infect.Dis. Jan;18(S1):S88–95, pmid=8148460</ref> He is a principal investigator of the FDA-approved open label safety and efficacy phase III drug study of Ampligen for treatment of chronic fatigue syndrome.<ref name="Amp 511">(2005), "Study of Ampligen in Chronic Fatigue Syndrome", U.S. National Institutes of Health, Sep, [http://clinicaltrials.gov/ct2/show/NCT00215813 20090106]</ref> According to the drug developer Hemispherx Biopharma, a [[New Drug Application]] for Ampligen treatment of chronic fatigue syndrome has been filed with the FDA but has not yet been approved.<ref>(1986), Business Description: HEM Research, Inc., [http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A& 20070225]</ref><ref>"Ampligen", Hemispherx Biopharma, [http://www.hemispherx.net/content/rnd/drug_candidates.htm 20080426]</ref>


Peterson was a member of the International Chronic Fatigue Syndrome Study Group that coauthored the most widely used clinical and research description of CFS,<ref name = Wyller>{{cite journal |author=Wyller VB |title=The chronic fatigue syndrome--an update |journal=Acta neurologica Scandinavica. Supplementum |volume=187 |issue= |pages=7-14 |year=2007 |pmid=17419822 |doi=10.1111/j.1600-0404.2007.00840.x |url=}}</ref> called the 1994 CDC definition, and the Fukuda definition.<ref name="CDC1994">{{cite journal | author = Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A | title = The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. | journal = Ann Intern Med | volume = 121 | issue = 12 | pages = 953-9 | year = 1994 | pmid=7978722|url=http://www.annals.org/cgi/content/full/121/12/953}}</ref> He is a coauthor of the ''Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols'' initiated by [[Health Canada]] and published by an international group of researchers in 2003.<ref name="carr">{{cite journal | author = Carruthers BM, et al. | title = Myalgic encephalomyalitis/chronic fatigue syndrome: Clinical working definition, diagnostic and treatment protocols | journal = Journal of Chronic Fatigue Syndrome | volume = 11 | issue = 1 | pages = 7–36 | year = 2003 | url = http://www.cfids-cab.org/MESA/ccpccd.pdf |format=PDF| doi = 10.1300/J092v11n01_02}}</ref><ref name="pmid "16935963">{{cite journal |author=Carruthers BM |title=Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works |journal=J. Clin. Pathol. |volume=60 |issue=2 |pages=117–9 |year=2007 |month=February |pmid=16935963 |doi=10.1136/jcp.2006.042754 |url=}}</ref><ref name="isbn "9780750688673">{{cite book | last = | first = | authorlink = | coauthors = Khot, Alex; Polmear, Andrew | title = Practical General Practice: Guidelines for Effective Clinical Management (5th New edition) | publisher = Elsevier Health Sciences | date = 24 April 2006 | location = | pages = 419-421| url = | doi = | id = | isbn = 9780750688673, 075068867X }}</ref>
Peterson was a member of the International Chronic Fatigue Syndrome Study Group that co-authored the most widely used clinical and research description of CFS,<ref>Wyller VB (2007), "The chronic fatigue syndrome--an update", Acta neurologica Scandinavica, 187(S):7-14, pmid=17419822</ref> called the 1994 CDC definition, and the Fukuda definition.<ref>Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994), "The chronic fatigue syndrome: a comprehensive approach to its definition and study", International Chronic Fatigue Syndrome Study Group, Ann Intern Med, 121(12):953-9, pmid=7978722 [http://www.annals.org/cgi/content/full/121/12/953 20090609]</ref> He is a co-author of the ''Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols'' initiated by [[Health Canada]] and published by an international group of researchers in [[2003]].<ref>Carruthers BM, Jain AK, DeMeirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles ACP, Sherkey JA, Van de Sande MI (2003), "Myalgic Encephalomyelitis / Chronic Fatigue Syndrome : Clinical Working case Definition, Diagnostic and Treatment Protocols", Journal of Chronic Fatigue Syndrome, 11(1):7–36, [http://www.cfids-cab.org/MESA/ccpccd.pdf 20090609]</ref><ref>Carruthers BM (2007), "Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works", J. Clin. Pathol., Feb;60(2):117–9, pmid=16935963</ref><ref>Khot A, Polmear A (2006), "Practical General Practice: Guidelines for Effective Clinical Management (5th New edition)", Elsevier Health Sciences, Apr24:419-421, ISBN 075068867X]</ref>


==Affiliations==   
==Affiliations==   
Line 21: Line 21:
In 1999 Peterson was commended by the Assembly and Senate of the State of Nevada, for his work and dedication to persons with chronic fatigue syndrome.<ref name="AJR14">(1999), "AJR14", Nevada Legislative Counsel Bureau, Apr 8, [http://www.leg.state.nv.us/70th/reports/History.cfm?BILLNAME=AJR14 20090217]</ref>
In 1999 Peterson was commended by the Assembly and Senate of the State of Nevada, for his work and dedication to persons with chronic fatigue syndrome.<ref name="AJR14">(1999), "AJR14", Nevada Legislative Counsel Bureau, Apr 8, [http://www.leg.state.nv.us/70th/reports/History.cfm?BILLNAME=AJR14 20090217]</ref>


==Selected publications==  
==Selected publications==
   
<div style="font-size:11px;">
*{{cite journal |author=Shetzline SE, Martinand-Mari C, Reichenbach NL, ''et al'' |title=Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome |journal=J. Interferon Cytokine Res. |volume=22 |issue=4 |pages=443–56 |year=2002 |month=April |pmid=12034027 |doi=10.1089/10799900252952235 |url=}} 
* Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Komaroff AL, Ritz J (1987), "Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome", J Immunol, Nov;139(10):3306–13, pmid=2824604, [http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=2824604 20090611]
*{{cite journal |author=Ablashi DV, Eastman HB, Owen CB, ''et al'' |title=Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients |journal=J. Clin. Virol. |volume=16 |issue=3 |pages=179–91 |year=2000 |month=May |pmid=10738137 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S1386653299000797}} 
* Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS (1991), "Chronic fatigue syndrome in northern Nevada", Rev Infect Dis, 13(S1):S39–44, pmid=1850542
*{{cite journal |author=Suhadolnik RJ, Peterson DL, O'Brien K, ''et al'' |title=Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome |journal=J. Interferon Cytokine Res. |volume=17 |issue=7 |pages=377–85 |year=1997 |month=July |pmid=9243369 |doi= |url=}} 
* Levine PH, Peterson D, McNamee FL, O'Brien K, Gridley G, Hagerty M, Brady J, Fears T, Atherton M, Hoover R (1992), "Does Chronic Fatigue Syndrome Predispose to Non-Hodgkin's Lymphoma?", Cancer Res Oct;52(S):S55l6-55l8
*{{cite journal |author=Suhadolnik RJ, Reichenbach NL, Hitzges P, ''et al'' |title=Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome |journal=In Vivo |volume=8 |issue=4 |pages=599–604 |year=1994 |pmid=7893988 |doi= |url=}} 
* Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, ''et al.'' (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S88–95, pmid=8148460
*{{cite journal |author=Suhadolnik RJ, Reichenbach NL, Hitzges P, ''et al'' |title=Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome |journal=Clin. Infect. Dis. |volume=18 Suppl 1 |issue= |pages=S96–104 |year=1994 |month=January |pmid=8148461 |doi= |url=}} 
* Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Müller WE, Schröder HC, Carter WA, ''et al.'' (1994), "Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S96–104, pmid=8148461
*{{cite journal |author=Strayer DR, Carter WA, Brodsky I, ''et al'' |title=A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome |journal=Clin. Infect. Dis. |volume=18 Suppl 1 |issue= |pages=S88–95 |year=1994 |month=January |pmid=8148460 |doi= |url=}} 
* Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Müller WE, ''et al.'' (1994), "Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome", In Vivo, 8(4):599–604, pmid=7893988
*{{cite journal |author=Paul H. Levine, Daniel Peterson, Faye L. McNamee, Karen O'Brien, Gloria Gridley, Mary Hagerty, Jane Brady, Thomas Fears, Martin Atherton, and Robert Hoover|title=Does Chronic Fatigue Syndrome Predispose to Non-Hodgkin's Lymphoma? |journal=CANCER RESEARCH (SUPPL.) |volume=52 |issue= |pages=55l6s-55l8s |year=1992 |month=October |pmid= |doi= |url=http://cancerres}}
* Suhadolnik RJ, Peterson DL, O'Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W (1997), "Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Jul;17(7):377–85, pmid=9243369
*{{cite journal |author=Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS |title=Chronic fatigue syndrome in northern Nevada |journal=Rev. Infect. Dis. |volume=13 Suppl 1 |issue= |pages=S39–44 |year=1991 |pmid=1850542 |doi= |url=}} 
* Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE (2000), "Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients", J. Clin. Virol., May;16(3):179–91, pmid=10738137 [http://linkinghub.elsevier.com/retrieve/pii/S1386653299000797 20090611] 
*{{cite journal |author=Caligiuri M, Murray C, Buchwald D, ''et al'' |title=Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome |journal=J. Immunol. |volume=139 |issue=10 |pages=3306–13 |year=1987 |month=November |pmid=2824604 |doi= |url=http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=2824604}}
* Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ (2002), "Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Apr;22(4):443–56, pmid=12034027
</div>
 
{{Wikidata|Q5218440}}


==References==
{{refs}}
{{refs}}


[[Category:Myalgic encephalomyelitis]]
[[Category:Myalgic encephalomyelitis]]
[[Category:Physician in the United States of America]]
[[Category:Physician in the United States of America]]

Latest revision as of 01:41, 7 May 2019

Daniel Peterson is an American physician in private practice in the state of Nevada, and has been described as a "pioneer" in the treatment of central nervous system infections[1] and chronic fatigue syndrome (CFS).[2] He graduated from the University of Rochester School of Medicine, Rochester, New York, in 1976 and was an intern and resident at the University of Utah Medical Center from 1976-1979. In 1979 he became a diplomat of the American Board of Internal Medicine.[3] He is president of Sierra Internal Medicine of Incline Village, established in 1981.[4]

Work on myalgic encephalomyelitis / chronic fatigue syndrome

Peterson with Paul Cheney, was a treating physician at Incline Village during an outbreak of chronic fatigue syndrome that began in 1984 in the Lake Tahoe region.[5] From 1984-87, the illness was recorded in 259 patients in the area by the two physicians. The Lake Tahoe outbreak became the subject of several studies by Peterson and others. In 1995 Peterson and other investigators started conducting a 10-year follow-up study on patients seen during the outbreak. The study results were published in 2001 by the Journal of Chronic Fatigue Syndrome.[6] In the 2000 CFS documentary I Remember Me, Peterson was interviewed about some of his experiences during the Lake Tahoe outbreak.[7]

In 1988, Peterson was the first physician to treat an extremely ill person diagnosed with CFS with the experimental drug Ampligen by obtaining compassionate use permission from the U.S. Food and Drug Administration. Quantitative improvement in the first patient enabled the next pilot study of Ampligen in CFS patients by Peterson and other researchers. During the 1990 Cambridge Easter Symposium on myalgic encephalomyelitis and chronic fatigue syndrome in the United Kingdom, Peterson described positive results in 15 patients who satisfied the 1988 Holmes criteria for CFS and also showed evidence of encephalopathy, after he treated them with Ampligen for approximately 6 months.[8][2] In 1990 and 1991 Peterson was one of four principal investigators for the FDA approved phase II randomized placebo controlled double blind study of the experimental intravenous drug Ampligen. The drug was administered in his Incline Village facility and three other sites.[9] Peterson and others reported there was statistically significant improvement in the patients receiving Ampligen.[10] He is a principal investigator of the FDA-approved open label safety and efficacy phase III drug study of Ampligen for treatment of chronic fatigue syndrome.[11] According to the drug developer Hemispherx Biopharma, a New Drug Application for Ampligen treatment of chronic fatigue syndrome has been filed with the FDA but has not yet been approved.[12][13]

Peterson was a member of the International Chronic Fatigue Syndrome Study Group that co-authored the most widely used clinical and research description of CFS,[14] called the 1994 CDC definition, and the Fukuda definition.[15] He is a co-author of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols initiated by Health Canada and published by an international group of researchers in 2003.[16][17][18]

Affiliations

Peterson was part of the founding board, and is a past president of the International Association for CFS/ME,[3] a professional organization advocating for the interests of CFS researchers and clinicians worldwide.[19][20] He is the medical director of the Whittemore Peterson Institute for Neuro-Immune Disease.[3] He is a member of the board of directors and the scientific advisory board of the HHV-6 Foundation,[1] a nonprofit organization promoting human herpesvirus 6 (HHV-6) associated scientific and clinical research.[21]

In 2003 he received the distinguished CFS/FM scientist, physician or healthcare worker Rudy Perpich award, and in 2007 received the Nelson Gantz Outstanding Clinician Award from the International Association for CFS/ME.[22]

In 1999 Peterson was commended by the Assembly and Senate of the State of Nevada, for his work and dedication to persons with chronic fatigue syndrome.[23]

Selected publications

  • Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Komaroff AL, Ritz J (1987), "Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome", J Immunol, Nov;139(10):3306–13, pmid=2824604, 20090611
  • Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS (1991), "Chronic fatigue syndrome in northern Nevada", Rev Infect Dis, 13(S1):S39–44, pmid=1850542
  • Levine PH, Peterson D, McNamee FL, O'Brien K, Gridley G, Hagerty M, Brady J, Fears T, Atherton M, Hoover R (1992), "Does Chronic Fatigue Syndrome Predispose to Non-Hodgkin's Lymphoma?", Cancer Res Oct;52(S):S55l6-55l8
  • Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al. (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S88–95, pmid=8148460
  • Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Müller WE, Schröder HC, Carter WA, et al. (1994), "Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S96–104, pmid=8148461
  • Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Müller WE, et al. (1994), "Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome", In Vivo, 8(4):599–604, pmid=7893988
  • Suhadolnik RJ, Peterson DL, O'Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W (1997), "Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Jul;17(7):377–85, pmid=9243369
  • Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE (2000), "Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients", J. Clin. Virol., May;16(3):179–91, pmid=10738137 20090611
  • Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ (2002), "Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Apr;22(4):443–56, pmid=12034027

Q5218440 at Wikidata  Interwiki via Wikidata


References

References:
  1. ↑ 1.0 1.1 (2004), "HHV-6 Foundation Board of Directors", HHV-6 Foundation, 20090318
  2. ↑ 2.0 2.1 Verrillo EF, Gellman LM (1998), "Chronic Fatigue Syndrome: A reatment Guide", Macmillan, 152p, ISBN=0312180667, 20090606
  3. ↑ 3.0 3.1 3.2 (2008), "Executive staff", The Whittemore Peterson Institute, 20090111
  4. ↑ (2008), "Sierra Internal Medicine", Dun and Bradstreet, 20090112
  5. ↑ Donaldson S, Snyderman N, Cheney P, Bell D, DeFreitas E, Johnson H, PWC's, Pollard P, Mrs. Dailor, Lee P (1996), "Sick & Tired - Chronic Fatiguue Syndrome", Primetime Live (tv), ABC News, Mar 27, 20090609
  6. ↑ Strickland PS, Levine PH, Peterson DL, O'Brien K, Fears T (2001), "Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an Outbreak", Journal of Chronic Fatigue Syndrome 9(3/4):3–14 20090609
  7. ↑ Snyder KA (2000), I Remember Me, Loka Motion Productions, Inc., 20090609
  8. ↑ Peterson DL, Strayer DR, Bastien SB, Henry B, Ablashi DV, Breaux EJ, Walters DJ, Gillespie DR, Carter WA, "Clinical Improvements Obtained with Ampligen in Patients with Severe Chronic Fatigue Syndrome and Associated Encephalopathy", in: Hyde BM (ed.) (1992), "The Clinical and Scientific Basis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome", Nightingale Research Foundation, Ottawa, Canada with editorial and conceptual advice from Levine P and Goldstein J., 724+23p, ISBN 0-9695662-0-4, ch.71, p.634-638
  9. ↑ Johnson H (1996), "Osler's web: inside the labyrinth of the chronic fatigue syndrome epidemic", New York: Crown Publishers, p385, ISBN 0-517-70353-X
  10. ↑ Strayer DR, Carter WA, Brodsky I, et al. (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin.Infect.Dis. Jan;18(S1):S88–95, pmid=8148460
  11. ↑ (2005), "Study of Ampligen in Chronic Fatigue Syndrome", U.S. National Institutes of Health, Sep, 20090106
  12. ↑ (1986), Business Description: HEM Research, Inc., 20070225
  13. ↑ "Ampligen", Hemispherx Biopharma, 20080426
  14. ↑ Wyller VB (2007), "The chronic fatigue syndrome--an update", Acta neurologica Scandinavica, 187(S):7-14, pmid=17419822
  15. ↑ Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994), "The chronic fatigue syndrome: a comprehensive approach to its definition and study", International Chronic Fatigue Syndrome Study Group, Ann Intern Med, 121(12):953-9, pmid=7978722 20090609
  16. ↑ Carruthers BM, Jain AK, DeMeirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles ACP, Sherkey JA, Van de Sande MI (2003), "Myalgic Encephalomyelitis / Chronic Fatigue Syndrome : Clinical Working case Definition, Diagnostic and Treatment Protocols", Journal of Chronic Fatigue Syndrome, 11(1):7–36, 20090609
  17. ↑ Carruthers BM (2007), "Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works", J. Clin. Pathol., Feb;60(2):117–9, pmid=16935963
  18. ↑ Khot A, Polmear A (2006), "Practical General Practice: Guidelines for Effective Clinical Management (5th New edition)", Elsevier Health Sciences, Apr24:419-421, ISBN 075068867X]
  19. ↑ Friedberg F, Sohl S, Schmeizer B (2007), "Publication trends in chronic fatigue syndrome: comparisons with fibromyalgia and fatigue: 1995-2004", J Psychosom Res, Aug;63(2):143–6, pmid=17662750
  20. ↑ David Tuller (2008), "Expert Q&A, Learning Firsthand about Chronic Fatigue Syndrome" Interview with Leonard Jason, Apr 30, 20090608
  21. ↑ "HHV-6 Foundation", National Institute of Neurological Disorders and Stroke, 20090215
  22. ↑ "Former IACFS/ME awardees", International Association for CFS/ME, 20090107
  23. ↑ (1999), "AJR14", Nevada Legislative Counsel Bureau, Apr 8, 20090217
Retrieved from "https://en.wikisage.org/w/index.php?title=Daniel_Peterson&oldid=8287"